3rd Nov 2016 16:47
LONDON (Alliance News) - NetScientific PLC on Thursday said portfolio company Vortex Biosciences has been granted a CE Mark for its circulating tumour cell capture system, the VTX-1 Liquid Biopsy System.
The system has also been registered as a Class 1 medical device with the US Food & Drug Administration.
"Both the CE Mark and FDA Class 1 registration are significant milestones achieved towards making VTX-1 commercially available in early 2017 and bringing us closer to the sale of the system in the clinical market in the US," said NetScientific Chief Executive Francois Martelet.
Shares in NetScientific closed untraded on Thursday, having last traded at 64.76 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Netscientific